Tortora F, Notariale R, Lang F, Manna C
As the first anti-obesity drug targeting multiple receptors, tirzepatide (Zepbound, Eli Lilly), a dual GIPR/GLP-1R agonist, was approved by the FDA in 2022
the only ASV identified for Staphylococcus mapped to Staphylococcus xylosus , and the only ASV found for UBA1819 mapped to Ruthenibacterium lactatiformans
At Perfect B, all peptides are sourced exclusively from licensed 503A compounding pharmacies
GLP-1 mimics the GLP-1 hormone to decrease hunger and improve satiety, supporting significant weight reduction while maintaining muscle mass
See the current patch formula and available Duori bundles before deciding what fits your goals